Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach
Background: Outbreak of COVID-19 has been recognized as a global health concern since it causes high rates of morbidity and mortality. No specific antiviral drugs are available for the treatment of COVID-19 till date. Drug repurposing strategy helps to find out the drugs for COVID-19 treatment from...
Saved in:
Main Authors: | Purushothaman Indu (Author), Marimuthu Ragavan Rameshkumar (Author), Narasingam Arunagirinathan (Author), Naif Abdullah Al-Dhabi (Author), Mariadhas Valan Arasu (Author), Savarimuthu Ignacimuthu (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2020-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antibacterial activity of peptides and bio-safety evaluation: in vitro and in vivo studies against bacterial and fungal pathogens
by: Mariadhas Valan Arasu, et al.
Published: (2023) -
Pharmacoeconomic analysis of the etravirine compared to raltegravir in treatment HIV-infected adult patients, previously treated with antiretroviral drugs
by: Y. I. Ashikhmin, et al.
Published: (2018) -
Editorial on Antimicrobial Resistance and its Prevalence
by: Mariadhas Valan Arasu
Published: (2021) -
Clinical resistance to dolutegravir assessed by next generation sequencing in pre-exposed raltegravir patients
by: Philippe Halfon, et al.
Published: (2018) -
Role of tipranavir in treatment of patients with multidrug-resistant HIV
by: Joshua D Courter, et al.
Published: (2010)